(NASDAQ: VRTX) Vertex Pharmaceuticals's forecast annual revenue growth rate of 10.8% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 113.47%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.09%.
Vertex Pharmaceuticals's revenue in 2026 is $11,723,300,000.On average, 33 Wall Street analysts forecast VRTX's revenue for 2026 to be $3,374,967,889,962, with the lowest VRTX revenue forecast at $2,997,180,550,603, and the highest VRTX revenue forecast at $3,764,172,576,716. On average, 26 Wall Street analysts forecast VRTX's revenue for 2027 to be $3,687,295,770,923, with the lowest VRTX revenue forecast at $2,943,392,158,431, and the highest VRTX revenue forecast at $4,261,968,923,138.
In 2028, VRTX is forecast to generate $4,060,262,452,493 in revenue, with the lowest revenue forecast at $3,132,412,687,526 and the highest revenue forecast at $4,889,161,873,370.